Efficacy and Safety of Two Different Enoxaparin Doses for Thromboprophylaxis in Non-Critically Ill Patients: A Randomized Controlled Trial

Conclusion: Enoxaparin dose of 60mg daily provide anti-factor Xa level higher than desired in most patients. In non-critically ill patients, the dose of 40mg is the proper dose for thromboprophylaxis.The trial was retrospectively registered on 05/18/2020 at the Iranian Registry on Clinical Trials (IRCT20130917014693N11).
Source: Iranian Journal of Pharmaceutical Research - Category: Drugs & Pharmacology Source Type: research